Tibes Lab

Acute leukemias are amongst the most deadly cancers, particularly acute myeloid leukemia (AML). Treatment options for the often elderly patients is still suboptimal and novel therapeutic approaches are urgently needed. Myelodysplastic Syndrome (MDS) is a myeloid stem cell disorder closely elated to AML and a fraction of MDS patients progress to AML. Myeloproliferative Neoplasm (MPNs) comprised of Myelofibrosis (MF/ PMF), Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are myloid neoplasms as well, that share certain features but are distinct diseases. The molcular pathogenesis of the myeloid disease group is partially overlapping an shared while each disease group harbors specific and distinct features.  

The Tibes Group has clinical and pre-clinical research projects in all disease areas. The clinical expertise and the experience of the PI have led to design and development of several clinical trial protocols and correlative laboratory studies. The experience of the PI as principal investigator on many phase I and II clinical trials in hematology and solid tumors with associated correlative studies, provides tremendous expertise and opportunity as well as a “realistic” perspective of accomplishable goals for translational cancer research and biomarker driven trials with correlative laboratory studies.

Our Mission

The Mission of the Tibes Lab is to contribute to the improvement of treatment for patients with myeloid malignancies. The laboratory research centers around identifying novel putative treatment targets in myeloid disorders and translate those into new therapy approaches. We achieve this by leveraging our labortory efforts with the clinical leukemia program to identify novel putative therapeutic targets. We apply functional genomic screens (RNAi, CRISP-CAS) to develop rational combinations that are mechanistically validated and translated into clinical trials. Our expertise in Drug Development and Experimental Therapeutics together with ongoing research projects create a unique translational leukemia and cancer research program.